KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis

摘要: __Abstract__ Background: Bowel cancer is the third most common in UK. Most bowel cancers are initially treated with surgery, but around 17% spread to liver. When this happens, sometimes liver tumour can be treated surgically, or chemotherapy may used shrink tumour make surgery possible. Kirsten rat sarcoma viral oncogene (KRAS) mutations some tumours less responsive treatment with biological therapies such as cetuximab. There a variety of tests available detect these mutations. These vary specific that they detect, amount mutation detect, the cells needed, time give result, error rate and cost. Objectives: To compare performance cost-effectiveness KRAS differentiating adults metastatic colorectal whose metastases confined unresectable and who benefit from first-line treatment cetuximab combination standard chemotherapy from those should receive alone.